Structure’s oral GLP-1 data in obesity set up the biotech as an M&A target

Friday’s four-week data readout for Structure’s GSBR-1290 in obesity suggest that the oral GLP-1 therapy could be competitive with others in the class from larger pharmas — and could set up the newly public biotech as a takeout target.

The top dose of GSBR-1290 from Structure Therapeutics Inc. (NASDAQ:GPCR) led to weight loss of 5.4% compared with 0.5% for placebo (exploratory p=0.013) after 28 days, with no discontinuations, serious adverse events or changes in liver function tests. The placebo-adjusted rate was 4.9% (90% CI: -7.8, -1.9)...